TP53 and gastric cancer: The human gastric cancer cell line NUGC-3 carrying a TP53 Y220C mutation was treated with increasing concentrations of PC14586, and a dose-dependent loss in binding to PAb240 and an increase in binding to PAb1620 were observed, whereas total p53 levels remained unchanged (Fig. 1C).